NCT04688983View on ClinicalTrials.gov

Study in Adult Ph-positive ALL

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

January 31, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2026

Conditions

Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG

Ponatinib

30 mg QD starting day 1, given continuously unless interruption required for toxicity

DRUG

Blinatumomab

A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.

DRUG

Imatinib

starting day 1, given orally at 400mg BID continuously for 8 weeks

All Listed Sponsors

lead

Cardiff University

OTHER

NCT04688983 - Study in Adult Ph-positive ALL | Biotech Hunter | Biotech Hunter